AI-Generated Summary

Aptamer Group plc has announced a significant development contract with a top 3 global pharmaceutical company to engineer its Optimer® binders for targeted radiopharmaceutical therapeutic applications. This £360,000 fee-for-service program focuses on an undisclosed cancer target, initially for PET imaging, with future potential for therapeutic use. The agreement expands Aptamer's Optimer® platform into the growing $7.5 billion targeted radiopharmaceuticals market, retaining licensing rights for future commercialization.

In a nutshell

This contract represents a strategic expansion for Aptamer Group, validating its Optimer® platform's versatility and potential in high-value therapeutic areas like targeted radiopharmaceuticals. For the broader industry, it highlights continued investment by major pharmaceutical players in innovative biotech platforms for next-generation drug development, particularly in oncology.

Source: News-Medical.net